The premarket action often provides investors and traders with a glimpse into the possibilities during the coming trading day and by that token, it could be a good move to perhaps take a look at the Xeris Biopharma Holdings Inc. (NASDAQ:XERS) stock.
Trading Data
On Thursday, XERS stock fell 7.32% to $1.52 with 6.24 million shares, compared to its average volume of 1.60 million shares. The stock moved within a range of $1.2500 – 1.6199 after opening trade at $1.50.
Key Details
The Xeris Biopharma (NASDAQ:XERS) stock was in action during premarket trading period and ended up with gains of as much as 5%. The company is involved in the development in neurology, gastroenterology and endocrinology therapies which are unique in nature. Yesterday, the company was in the news after it announced that it was going to present new data with regards to the logics study of Recorlev and new burden of illness in Cushing ’s syndrome at an event.
The event in question is the American Association of Clinical Endocrinology (AACE) Annual Meeting that commenced yesterday and will conclude on May 14. The news came as a big boost for the stock as it attracted the attention of investors and ended up with gains in the premarket period. At this point in time, it could be a good move for investors to consider adding the Xeris stock to their watch lists.
Technical Data
XERS stock is trading below the 20-Day and 50-Day Moving averages of $2.15 and $2.45 respectively. Moreover, the stock is trading below 200-Day moving average of $2.36.
